| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to biotechnology, particularly to genetic engineering, and may be used in preparing drugs for hepatitis C. What has been offered is using a pegylated methionine-containing form of N-terminal truncated IL-29 variant with a substituted cysteine residue in a position corresponding to position 171 of an amino acid sequence of a wild-type mature protein expressed in a heterologous system in the form of high homogenous preparations when preparing a drug for hepatitis C. n EFFECT: invention may be used in preparing the drugs for hepatitis C. n 3 cl, 37 tbl, 45 ex |